Your shopping cart is currently empty

LTA4H-IN-4 (compound 3) is an orally active inhibitor of LTA4H. It exhibits an IC50 value of 156 μM against hERG and is applicable for inflammation-related research.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | LTA4H-IN-4 (compound 3) is an orally active inhibitor of LTA4H. It exhibits an IC50 value of 156 μM against hERG and is applicable for inflammation-related research. |
| In vitro | LTA4H-IN-4 (compound 3) at concentrations ranging from 0 to 10 μM over a period of 4 hours completely inhibits the release of LTB4 in primary peripheral blood mononuclear cells (PBMCs) following stimulation by a calcium ionophore. |
| In vivo | LTA4H-IN-4 (compound 3), administered at 0-300 mg/kg twice daily with a 10-hour interval for 7 days either intravenously or orally, demonstrates significant oral activity in arthritis mouse models, as well as in rats and dogs, without notable changes in animal weight or any significant adverse effects observed in toxicological studies. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.